The Food and Drug Administration named a longtime pharmaceutical executive to run the agency’s drug program. Dr.

We recently compiled a list of 11 Best Future Stocks to Buy Now. Ultragenyx Pharmaceutical Inc. stands first on our list.

Tidmarsh will temporarily guide CBER’s regulatory activities while the FDA searches for a permanent department lead.

For University of Montana marketing researcher Jesse King, commercials – namely pharmaceutical advertisements – are intensely ...

Dr George Tidmarsh, a former pharmaceutical executive who joined the FDA this month, will take over Prasad’s role temporarily.

Oral, non-opioid drug candidate advancing through Phase 1 and nearing completion of the single ascending dose (SAD) portion ...

Analysts say the departure of the CBER head may alleviate overhang in the cell and gene therapy space. Vinay Prasad, head of the Center for Biologics Evaluation and Research (CBER) at the US Food and ...

Vinay Prasad, a top FDA official, suddenly departed after a series of controversial decisions about a Duchenne gene therapy ...

After a decade of development, a Kansas City-based pharmaceutical company is on the brink of submitting its ADHD medication ...

FDA inspections in India have been accelerating, but 160 plants are overdue, including some which haven't been inspected since 2015, yet continue shipping pain pills, antibiotics, and other ...

The Pharmaceutical Research and Manufacturers of America (PhRMA), the main drug industry lobbying group in the U.S., said in a statement Friday that it strongly opposes the FDA's decision.